**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 60358

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Impact of different stereoisomers of inositol on insulin sensitivity of gestational diabetes mellitus patients**

He J *et al*. Stereoisomers of inositol of GDM patients

Jing He, Yan-Li Zhang, Li-Ping Wang, Xiao-Chun Liu

**Jing He, Yan-Li Zhang, Li-Ping Wang, Xiao-Chun Liu,** Department of Obstetrics and Gynecology, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan 030032, Shanxi Province, China

**Author contributions:** He J and Zhang YL designed this study and wrote the article; Wang LP drafted the work and collected the data; Liu XC revised the paper for important intellectual content.

**Corresponding author: Xiao-Chun Liu, MD, Associate Professor,** Department of Obstetrics and Gynecology, Shanxi Bethune Hospital, Shanxi Medical University, No. 99 Longcheng Street, Taiyuan 030032, Shanxi Province, China. tyxchliu@163.com

**Received:** October 27, 2020

**Revised:** November 29, 2020

**Accepted:** December 6, 2020

**Published online:**

**Abstract**

BACKGROUND

Inositol is a hexa-carbon polyol, a naturally soluble vitamin, often found in various foods.

AIM

To discuss the impact of different stereoisomers of inositol on insulin sensitivity of gestational diabetes mellitus (GDM) patients.

METHODS

Eighty GDM pregnant women were divided into four groups according to their treatment received: A group (placebo folic acid 400 μg/d), B group [myo-inositol (MI) 1500 mg, twice a day], C group [D-chiro-inositol (DCI) 250 mg, twice a day], and D group (inositol MI and inositol DCI 1500 mg/250 mg, twice a day). Each patient routinely used dietary guidance adjustments and did some safe and effective aerobic exercise in addition to receiving placebo or inositol from GDM diagnosis to delivery. Triglyceride, total cholesterol, fasting plasma glucose, oral glucose tolerance test postprandial glucose (2 h postprandial blood glucose), fasting insulin, fasting plasma glucose, and glycosylated hemoglobin levels and Homeostasis Model Assessment-insulin resistance (HOMA-IR) and Homeostasis Model Assessment-insulin sensitivity index (HOMA-ISI) scores were determined before treatment and 8 wk after treatment onset. Adverse maternal and infant outcomes, including hypoglycemia, excessive amniotic fluid, premature infants, macrosomia, fetal distress *etc*., were also recorded.

RESULTS

There was no statistical difference in the baseline data of each group. The levels of 2 h blood glucose, glycosylated hemoglobin, fasting insulin, total cholesterol, and triglyceride in the B, C, and D groups were significantly lower than those in the control group (A group) after treatment (*P* < 0.05). Moreover, compared with the B group, the level of the above indexes in the C and D groups decreased more significantly, and the differences were statistically significant (*P* < 0.05). The HOMA-IR of B, C, and D groups decreased significantly, and the HOMA-ISI increased significantly compared with the A group, and the differences were statistically significant (*P* < 0.05), among which the decrease of HOMA-IR and the increase of HOMA-ISI were more significant in the C and D group compared with the B group (*P* < 0.05). The occurrence rate of adverse maternal and infant outcomes in the C and D group was significantly lower than that in the control group (A group), and the differences were statistically significant (*P* < 0.05).

CONCLUSION

Treatment with different inositol stereoisomers (inositol MI and inositol DCI) can improve insulin sensitivity and reduce insulin resistance in diabetic patients, and inositol DCI has a better curative effect than inositol MI.

**Key Words:** Gestational diabetes mellitus; Myo-inositol; Insulin resistance during pregnancy

He J, Zhang YL, Wang LP, Liu XC. Impact of different stereoisomers of inositol on insulin sensitivity of gestational diabetes mellitus patients. *World J Clin Cases* 2020; In press

**Core Tip:** We compared the impact of different stereoisomers of inositol on insulin sensitivity and prognosis of gestational diabetes mellitus patients.

**INTRODUCTION**

Inositol, a hexa-carbon polyol, is a naturally soluble vitamin often found in various foods. It has been listed as an insulin sensitizer. There are nine different isomers of inositol, of which the most representative in the human body are myo-inositol (MI) and D-chiro-inositol (DCI). The occurrence of some effects of insulin may include the participation of small molecule inositol phosphate polymer conductors. The conductor is produced by hydrolysis of glycosylated phosphatidylinositol ester (GPIs) located on the outer layer of the cell membrane. As a result, the released inositol phosphoglycan enters the cell and affects the metabolic process inside the cell. Studies have shown that inositol and inositol glycan intake can have beneficial effects on metabolism, hormone levels, and ovarian function[1,2]. A recent study showed that the supplementation of inositol significantly improved insulin resistance (IR) in gestational diabetes mellitus (GDM) patients[3], but the effects of chiral inositol (DCI) on IR in GDM have not been reported.

In this cohort study, the impact of different stereoisomers of inositol on insulin sensitivity and prognosis of GDM patients were determined.

**MATERIALS AND METHODS**

***Research subjects***

All 80 GDM patients in our hospital were treated with diet guidance and safe and effective aerobic exercise. The selected cases all met the diagnostic standard of GDM in China. In the 24-28 wk of gestation, 75 g glucose loading was used for the oral glucose tolerance test (OGTT) for pregnant women. OGTT diagnostic thresholds were as follows: The blood glucose values of empty stomach, feeding 1 h, and feeding 2 h of 5.1, 10.0, and 8.5 mmol/L, respectively. Any blood sugar that reached or exceeded the above threshold was diagnosed as GDM. Patients were excluded if pregnancy complications were present or if there was a history of alcohol or tobacco use or other bad habits prior to pregnancy.

***Clusters and interventions***

Eighty GDM pregnant women were divided into four groups according to their treatment received: A group (placebo folic acid 400 μg/d), B group (inositol MI 1500 mg, twice a day), C group (inositol DCI 250 mg, twice a day), and D group (inositol MI and inositol DCI 1500 mg/250 mg, twice a day). Each patient routinely used dietary guidance adjustments and did some safe and effective aerobic exercise in addition to receiving placebo or inositol from diagnostic GDM to delivery.

***Mensuration of relevant indicators***

After GDM diagnosis and 8 wk of treatment respectively measuring the Triglyceride, total cholesterol, fasting plasma glucose (FPG), OGTT postprandial glucose (2 h postprandial blood glucose), fasting insulin (FINS), FPG, and glycosylated hemoglobin levels were determined and the Homeostasis Model Assessment (HOMA)-IR index and HOMA-insulin sensitivity index (HOMA-ISI): HOMA-IR = FINS × FPG /22. 5, HOMA-ISI = 1/ FINS × FPG were calculated before treatment and 8 wk after treatment onset. Adverse maternal and infant outcomes, including hypoglycemia, hydramnion, premature infants, macrosomia, fetal distress, *etc*., were recorded.

***Statistical methods***

SPSS 22.0 software (Armonk, NY, United States) was used for statistical processing and adopting the analysi*s* of variance. All information is expressed as mean ± standard deviation (x ± s). The logarithm of blood insulin was taken, accounting for the data. *P* < 0.05 was the standard of statistical significance.

**RESULTS**

***Comparison of general material***

All patients in the four groups had no previous history or family history of diabetes. There was no statistical difference when comparing age, gestational weeks, and blood pressure during pregnancy. There was no difference in body mass index among the A, B, C, and D groups (*P* > 0.05). Overall, there was no statistical difference in baseline data, and follow-up studies were able to continue (Table 1).

***Comparison of metabolic parameters of glycolipid***

The level of the 2 h postprandial glucose, glycosylated hemoglobin, fasting insulin level, total cholesterol, and triglyceride in the B, C, and D groups decreased significantly compared with those before treatment, and they were significantly lower than those of the control group (A group), indicating statistical difference (*P* < 0.05). Moreover, compared with the B group, the above index level of the C and D groups decreased more significantly, and the differences were statistically significant (*P* < 0.05) (Table 2).

***Comparison of HOMA steady state model evaluation***

HOMA model has been widely used to evaluate insulin sensitivity, IR level, and islet B cell function in diabetic patients. The difference between HOMA-IR and HOMA-ISI was determined. There was no significant difference in HOMA-IR and HOMA-ISI among the A, B, C, and D groups before treatment. After treatment, the HOMA-IR of B, C, and D groups was significantly lower than that of the A group (*P* < 0.05), and the HOMA-ISI was significantly higher (*P* < 0.05). Among these, the decrease of HOMA-IR and the increase of HOMA-ISI were more significant in the C and D groups compared with the MI treatment group (B group), and the differences were statistically significant (*P* < 0.05) (Table 3).

***Comparison of the occurrence rate of adverse maternal and infant outcomes***

Fisher accurate test results showed that the difference of the occurrence rate of adverse maternal and infant outcomes in the four groups was statistically significant. Comparing two by two, the results indicated that compared with the A group, there was a statistically significant difference of the occurrence rate of adverse event in the C and D groups (*P* < 0.05). The details are shown in Table 4 and Table 5.

**DISCUSSION**

GDM refers to diabetes mellitus that occurs or is discovered during pregnancy, but glucose metabolism is normal or potential glucose tolerance is abnormal before pregnancy[4]. GDM can cause serious harm to pregnant women, fetuses, and newborns. It often causes pregnancy hypertension disease, excessive amniotic fluid, macrosomia, neonatal hypoglycemia, neonatal respiratory distress syndrome, and other maladies. GDM pregnant women and their offspring also have a significantly increased long-term risk of type 2 diabetes. The World Health Organization listed GDM as an independent type of diabetes in 1979. The incidence of GDM is not consistently reported around the world, but at l%-5% in our country, it is increasing year by year.

Increased IR[5] during pregnancy is recognized as a major pathophysiological mechanism of GDM. Pregnancy leads to a decline in insulin sensitivity in the body, which is known as IR. Physiological IR[6] can provide more glucose to promote fetal growth and meet the maternal central nervous system's dependence on certain blood glucose levels. However, abnormal IR during pregnancy can lead to abnormal metabolism of blood sugar and blood lipids, which can lead to obesity, GDM, gestational hypertension, and fetal intrauterine growth and development disorders, which are also closely related to the occurrence of long-term metabolic diseases in both mother and child. GDM pregnant women have a weaker biological response to insulin than women with normal glucose tolerance[7]. IR is caused by many factors, mainly the blocking or weakening of insulin signal transduction[8]. Impairments in the insulin receptor, insulin receptor substrate, and phosphatidylinositol 3 kinase function are important mechanisms of IR. One study reported that a pregnancy supplement significantly improved IR in GDM patients[3]. In that study, pregnant women with GDM were given inositol (MI). This group had significantly improved glucose and lipid metabolism and IR compared with the control group, which fully demonstrated the clinical value of inositol in pregnant women with GDM.

DCI is one of the nine isomers of inositol with optical rotation. The DCI pure product is a white powder that is soluble in water. In nature, DCI occurs in the form of compounds in buckwheat, soybeans, and other plants and insects. Ortmeyer *et al*[7] observed the acute effects of chemically synthesized DCI on blood glucose in rats. They treated streptozotocin (STZ) rats with DCI (10 mg/kg, intragastric administration), which reduced blood glucose levels by 30%-40%. In another study, the treatment with DCI (15 mg/kg) reduced the 120 min blood glucose of diabetic rats. Kawa *et al*[8] treated STZ rats with buckwheat extract containing DCI and showed that after receiving 15-20 mg/kg DCI 90 min, blood glucose decreased by 12%-19%. At the same time, it was found that giving DCI to normal rats in advance could reduce the increase in glucose after a glucose load. However, the effect of DCI on insulin resistance in GDM has not been reported[9-11].

In this study, we investigated the effects of different inositol stereoisomers (MI and DCI) on insulin sensitivity in GDM patients[12]. We found that MI or DCI simultaneously improved glycolipid metabolism in the HOMA steady state model, which significantly reduced the HOMA-IR value and improved the HOMA-ISI value[13,14]. These findings show that different inositol stereoisomers can increase insulin sensitivity and reduce IR in patients with GDM, thus having a clear therapeutic effect on GDM patients[15]. Further study found that compared with the effects in the MI treatment group, the decrease in HOMA-IR, the increase in HOMA-ISI, and the improvement of glucose metabolism in the DCI group were more significant and could lead to better maternal and infant outcomes. That is, DCI had a better curative effect on GDM pregnant women.

Sanchez-Arias *et al*[10] confirmed that the GPI-dependent insulin signaling pathway is impaired in STZ rats. The GPI level in hepatocytes isolated from STZ rats was lower than that in the GPI control group. STZ-induced diabetic rats[16-18] also blocked GPI hydrolysis of the insulin response, thus reducing the release of inositol phosphoglycan in the DCI group. Therefore, there is a defect in the reduction of inositol conversion to a differential isomer in insulin-sensitive tissues under type 2 diabetes mellitus. Moreover, Ostlund *et al*[11] found a certain concentration of DCI in normal human blood and urine, while almost no DCI was detected in the blood of type 2 diabetes patients. The content in their urine was many times higher than that of normal people. These results show that these patients may have metabolic disorders, resulting in overly fast DCI loss and blockage of insulin signaling[19]. Thus, DCI treatment can directly supplement its *in vivo* deficiencies. It can correct this deficiency through GPI-dependent insulin signaling pathways and increase the effectiveness of insulin, reducing blood sugar[20]. The purpose of this study was to explore new treatment methods that can reduce IR in patients with GDM. The specific reasons why these two stereoisomers of inositol affect insulin signaling need to be further explored.

**CONCLUSION**

In conclusion, treatment of different inositol stereoisomers (inositol MI and inositol DCI) can improve insulin sensitivity and reduce IR in diabetic patients. The inositol DCI was more effective in GDM than inositol MI.

**ARTICLE HIGHLIGHTS**

***Research background***

Inositol has nine different isomers, of which the most representative of the human body are myoinositol (MI) and D-chiro-inositol (DCI).

***Research motivation***

The supplementation of inositol significantly improved insulin resistance in gestational diabetes mellitus (GDM) patients, and the effects of DCI on insulin resistance in GDM have not been reported.

***Research objectives***

Discuss the impact of different stereoisomers of inositol on insulin sensitivity of GDM patients.

***Research methods***

Eighty GDM pregnant women were divided into four groups according to their specified treatment regimen.

***Research results***

There was no statistical difference in the baseline data of each group. The levels of 2 h blood glucose, glycosylated hemoglobin, fasting insulin, total cholesterol, and triglyceride in the B, C, and D groups were significantly lower than those in the control group (A group) after treatment (*P* < 0.05).

***Research conclusions***

Treatment of different inositol stereoisomers (inositol MI and inositol DCI) can improve insulin sensitivity and reduce insulin resistance in diabetic patients. The inositol DCI was more effective in treating GDM than inositol MI.

***Research perspectives***

The treatment of diabetes is diversified.

**REFERENCES**

1 **Corrado F**, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. *Diabet Med* 2011; **28**: 972-975 [PMID: 21414183 DOI: 10.1111/j.1464-5491.2011.03284.x]

2 **Asimakopoulos G**, Pergialiotis V, Anastasiou E, Antsaklis P, Theodora M, Vogiatzi E, Kallergi A, Sindos M, Loutradis D, Daskalakis G. Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial. *Trials* 2020; **21**: 633 [PMID: 32646482 DOI: 10.1186/s13063-020-04561-2]

3 **Crawford TJ**, Crowther CA, Alsweiler J, Brown J. Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes. *Cochrane Database Syst Rev* 2015; **(12)**: CD011507 [PMID: 26678256 DOI: 10.1002/14651858.CD011507.pub2]

4 **Campbell I**, Campbell H. Mechanisms of insulin resistance, mitochondrial dysfunction and the action of the ketogenic diet in bipolar disorder. Focus on the PI3K/AKT/HIF1-a pathway. *Med Hypotheses* 2020; **145**: 110299 [PMID: 33091780 DOI: 10.1016/j.mehy.2020.110299]

5 **Fraticelli F**, Celentano C, Zecca IA, Di Vieste G, Pintaudi B, Liberati M, Franzago M, Di Nicola M, Vitacolonna E. Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial. *Acta Diabetol* 2018; **55**: 805-812 [PMID: 29774465 DOI: 10.1007/s00592-018-1157-4]

6 **McLaurin J**, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. *J Biol Chem* 2000; **275**: 18495-18502 [PMID: 10764800 DOI: 10.1074/jbc.M906994199]

7 **Ortmeyer HK**, Huang LC, Zhang L, Hansen BC, Larner J. Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys. *Endocrinology* 1993; **132**: 646-651 [PMID: 8425484 DOI: 10.1210/endo.132.2.8425484]

8 **Kawa JM**, Taylor CG, Przybylski R. Buckwheat concentrate reduces serum glucose in streptozotocin-diabetic rats. *J Agric Food Chem* 2003; **51**: 7287-7291 [PMID: 14640572 DOI: 10.1021/jf0302153]

9 **Heni M**, Eckstein SS, Schittenhelm J, Böhm A, Hogrefe N, Irmler M, Beckers J, Hrabě de Angelis M, Häring HU, Fritsche A, Staiger H. Ectopic fat accumulation in human astrocytes impairs insulin action. *R Soc Open Sci* 2020; **7**: 200701 [PMID: 33047031 DOI: 10.1098/rsos.200701]

10 **Sanchez-Arias JA**, Sanchez-Gutierrez JC, Guadaño A, Alvarez JF, Samper B, Mato JM, Feliu JE. Impairment of glycosyl-phosphatidylinositol-dependent insulin signaling system in isolated rat hepatocytes by streptozotocin-induced diabetes. *Endocrinology* 1992; **131**: 1727-1733 [PMID: 1396318 DOI: 10.1210/endo.131.4.1396318]

11 **Ostlund RE Jr**, McGill JB, Herskowitz I, Kipnis DM, Santiago JV, Sherman WR. D-chiro-inositol metabolism in diabetes mellitus. *Proc Natl Acad Sci USA* 1993; **90**: 9988-9992 [PMID: 8234346 DOI: 10.1073/pnas.90.21.9988]

12 **Zhou L**, Zhang R, Yang S, Zhang Y, Shi D. Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice. *Endocr Connect* 2020; **9**: 939-945 [PMID: 33006955 DOI: 10.1530/EC-20-0295]

13 **Natamba BK**, Namara AA, Nyirenda MJ. Burden, risk factors and maternal and offspring outcomes of gestational diabetes mellitus (GDM) in sub-Saharan Africa (SSA): a systematic review and meta-analysis. *BMC Pregnancy Childbirth* 2019; **19**: 450 [PMID: 31779584 DOI: 10.1186/s12884-019-2593-z]

14 **McCormack C**, Leemaqz S, Furness D, Dekker G, Roberts CT. Do raised two-hour pre-pregnancy insulin levels confer the same risks of developing GDM, as raised fasting levels, in recurrent miscarriage patients? *J Obstet Gynaecol* 2020; **40**: 803-807 [PMID: 31790316 DOI: 10.1080/01443615.2019.1672139]

15 **Tian Y**, Zhang S, Huang F, Shi F, Li Y, Chen X, Zhang C, Zhong H, Ma W, Liu C, Niu C, Xue X, Ma L. Glycemic qualification rate and frequency of self-monitoring blood glucose glycemic qualification rate and frequency of self-monitoring blood glucose (SMBG) in women with gestational diabetes mellitus (GDM). *Diabetes Res Clin Pract*2020; **170**: 108482 [PMID: 32998018 DOI: 10.1016/j.diabres.2020.108482]

16 **Facchinetti F**, Cavalli P, Copp AJ, D'Anna R, Kandaraki E, Greene NDE, Unfer V; Experts Group on Inositol in Basic and Clinical Research. An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs). *Expert Opin Drug Metab Toxicol* 2020; **16**: 1187-1198 [PMID: 32966143 DOI: 10.1080/17425255.2020.1828344]

17 **Wang H**, Raleigh DP. General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers. *PLoS One* 2014; **9**: e104023 [PMID: 25260075 DOI: 10.1371/journal.pone.0104023]

18 **Celentano C**, Matarrelli B, Pavone G, Vitacolonna E, Mattei PA, Berghella V, Liberati M. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. *J Matern Fetal Neonatal Med* 2020; **33**: 743-751 [PMID: 30558466 DOI: 10.1080/14767058.2018.1500545]

19 **Jatavan P**, Lerthiranwong T, Sekararithi R, Jaiwongkam T, Kumfu S, Chattipakorn N, Tongsong T. The correlation of fetal cardiac function with gestational diabetes mellitus (GDM) and oxidative stress levels. *J Perinat Med* 2020; **48**: 471-476 [PMID: 32286249 DOI: 10.1515/jpm-2019-0457]

20 **Samsuddin S**, Arumugam PA, Md Amin MS, Yahya A, Musa N, Lim LL, Paramasivam SS, Ratnasingam J, Ibrahim L, Chooi KC, Tan A, Tan PC, Omar SZ, Samingan N, Ahmad Kamar A, Anuar Zaini A, Jalaluddin MY, Vethakkan SR. Maternal lipids are associated with newborn adiposity, independent of GDM status, obesity and insulin resistance: a prospective observational cohort study. *BJOG* 2020; **127**: 490-499 [PMID: 31778255 DOI: 10.1111/1471-0528.16031]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Bethune Hospital of Shanxi Province Institutional Review Board [Approval No. YXLL-2020-062].

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** October 27, 2020

**First decision:** November 20, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kramer JR, Sogabe I **S-Editor:** Zhang L **L-Editor:** Filipodia **P-Editor:**

**Table 1 Comparison of each groups of general material**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** | **A, *n* = 20** | **B, *n* = 20** | **C, *n* = 20** | **D, *n* = 20** | ***F*** | ***P* value** |
|  Age in yr | 27.61 ± 2.23 | 27.37 ± 2.16 | 26.82 ± 2.33 | 27.14 ± 1.99 | 0.4766 | 0.6995 |
| Wk of pregnancy  | 39.29 ± 1.58 | 39.45 ± 1.42 | 38.65 ± 1.53 | 39.32 ± 1.52 | 1.122 | 0.3457 |
| BMI in kg/m2 | 21.27 ± 2.63 | 21.36 ± 2.11 | 20.35 ± 1.53 | 20.69 ± 1.95 | 1.057 | 0.3727 |
| Systolic pressure in mmHg | 115 ± 10 | 111 ± 8 | 109 ± 6 | 110 ± 9 | 1.969 | 0.1257 |
| Diastolic pressure in mmHg | 71 ± 8 | 73 ± 8 | 72 ± 7 | 73 ± 9 | 0.2842 | 0.8366 |

Data are presented as mean ± standard deviation. A: Control group; B: Myo-inositol treatment group; C: D-chiro-inositol treatment group; D: Myo-inositol + D-chiro-inositol treatment group. BMI: Body mass index.

**Table 2 Comparison of blood glucose indicators of patients in each group before treatment and after treatment**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** | **A, *n* = 20** | **B, *n* = 20** | **C, *n* = 20** | **D, *n* = 20** | ***F*** | ***P* value** |
| Fasting glucose in mmol/L | Before treatment | 5.52 ± 1.27 | 5.26 ± 1.23 | 5.28 ± 1.23 | 5.25 ± 1.26 | 0. 2094 | 0.8896 |
| After treatment | 4.94 ± 1.14 | 4.97 ± 1.20 | 4.88 ± 0.99 | 4.77 ± 1.11 | 0.1260 | 0.9444 |
| Two h postprandial glucose in mmol/L | Before treatment | 8.52 ± 2.57 | 8.61 ± 2.25 | 8.72 ± 2.38 | 8.89 ± 2.57 | 0.2764 | 0.8423 |
| After treatment | 7.87 ± 1.12 | 5.13 ± 1.40 | 4.71 ± 1.24 | 4.69 ± 1.20 | 30.12 | < 0.0001 |
| Glycosylated hemoglobin, % | Before treatment | 5.72 ± 2.63 | 5.63 ± 2.59 | 5.78 ± 2.53 | 5.55 ± 2.27 | 0.0324 | 0.9921 |
| After treatment | 5.57 ± 1.77 | 4.93 ± 1.54 | 4.58 ± 1.44 | 4.47 ± 1.20 | 2.178 | 0.0475 |
| FINS in mmol/L | Before treatment | 12.76 ± 1.85 | 12.97 ± 2.01 | 12.63 ± 1.73 | 12.53 ± 1.75 | 0.2136 | 0.8867 |
| After treatment | 12.35 ± 1.76 | 10.56 ± 1.12 | 9.45 ± 1.71 | 9.86 ± 0.96 | 3.154 | 0.0296 |
| TC in mmol/L | Before treatment | 7.26 ± 0.62 | 7.42 ± 0.71 | 7.35 ± 0.83 | 7.25 ± 0.67 | 0.2553 | 0.8573 |
| After treatment | 7.12 ± 0.67 | 5.18 ± 0.45 | 5.26 ± 0.52 | 5.33 ± 0.55 | 56.96 | < 0.0001 |
| TG in mmol/L | Before treatment | 3.43 ± 0.52 | 3.31 ± 0.55 | 3.52 ± 0.64 | 3.63 ± 0.55 | 1.147 | 0.3356 |
| After treatment | 3.13 ± 0.46 | 2.48 ± 0.48 | 2.13 ± 0.50 | 2.39 ± 0.42 | 16.65 | < 0.0001 |

Data are presented as mean ± standard deviation. FINS: Fasting insulin; TC: Total cholesterol; TG: Triglyceride.

**Table 3 Comparison of homeostasis model assessment steady state model of each group**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  **Group** | **A, *n* = 20** | **B, *n* = 20** | **C, *n* = 20** | **D, *n* = 20** | ***F*** | ***P* value** |
| Before treatment  | HOMA-IR | 8.47 ± 0.99 | 8.32 ± 1.01 | 8.51 ± 0.95 | 8.44 ± 0.90 | 0.144 | 0.9330 |
| HOMA-ISI | -4.34 ± 0.47 | -4.72 ± 0.52 | -4.56 ± 0.55 | -4.77 ± 0.56 | 2.708 | 0.0510 |
| After treatment | HOMA-IR | 3.78 ± 0.85 | 3.12 ± 0.69 | 2.92 ± 0.53 | 2.85 ± 0.77 | 6.942 | 0.003 |
| HOMA-ISI | -0.86 ± 0.32 | -0.54 ± 0.26 | -0.37 ± 0.38 | -0.32 ± 0.29 | 7.844 | 0.002 |

Data are presented as mean ± standard deviation. A: Control group; B: Myo-inositol treatment group; C: D-chiro-inositol treatment group; D: Myo-inositol + D-chiro-inositol treatment group; HOMA-IR: Homeostasis model assessment insulin resistance; HOMA-ISI: Homeostasis model assessment insulin sensitivity index.

**Table 4 The occurrence rate of adverse maternal and infant outcomes in each group**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Hypoglycemia** | **Excessive amniotic fluid** | **Premature infants** | **Macrosomia** | **Fetal distress** | **Occurrence rate** |
| A | 1 (11) | 1 (11) | 1 (11) | 3 (11) | 1 (11) | 7 (63.6) |
| B | 0 | 1 (11) | 0 | 1 (11) | 0 | 2 (18.2) |
| C | 0 | 1 (11) | 0 | 0 | 0 | 1 (9.1) |
| D | 0 | 0 | 1 (11) | 0 | 0 | 1 (9.1) |

**Table 5 Comparison of adverse outcomes in different groups**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Occurrence rate** | ***P* value** | **1*P*value** | **2*P*value** | **3*P* value** |
| A | 7 (63.6) | 0.045 |  |  |  |
| B | 2 (18.2) |  | 0.135 |  |  |
| C | 1 (9.1) |  | 0.047 | 1.000 |  |
| D | 1 (9.1) |  | 0.047 | 1.000 | 1.000 |

P: Overall comparison of four groups; 1*P*: A groups; 2*P*: B groups; 3*P*: C groups.